Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Angela Moliterni"'
Autor:
Romano Demicheli, Maria Grazia Daidone, Patrizia Boracchi, Angela Moliterni, Federico Ambrogi, Danila Coradini, Ilaria Ardoino, Elia Biganzoli
Publikováno v:
The Breast. 24:294-297
Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf5923c3c57aee20c94f23546a449209
https://doi.org/10.1016/j.breast.2015.01.007
https://doi.org/10.1016/j.breast.2015.01.007
Autor:
Gabriella Mariani, Silvia Damian, Angela Moliterni, Matteo Duca, Giulia Bianchi, Laura Ferrari, Sara Cresta, Stefano Cavalieri, Filippo de Braud, Giuseppe Capri, Pinuccia Valagussa, Giulia Galli
Publikováno v:
The breast journal. 25(2)
The efficacy of anthracycline- and taxane-based chemotherapy for perioperative treatment of breast cancer (BC) has been established. No superiority of a cytotoxic regimen has been demonstrated, provided that administration of an anthracycline and a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8fc4fa60dc7e558554723014bd1431
https://pubmed.ncbi.nlm.nih.gov/30810258
https://pubmed.ncbi.nlm.nih.gov/30810258
Autor:
Rosaria Orlandi, Marilena V. Iorio, Angela Moliterni, Maria Luisa Carcangiu, Elvira D'Ippolito, Ilaria Plantamura, Stefania Cresta, Elda Tagliabue, F. de Braud, Anna Tessari
Publikováno v:
Cancer Research. 73:P4-07
miR-9 has been described as an oncogenic microRNA associated to a metastatic phenotype and able to induce EMT (epithelial-to-mesenchymal transition) through direct targeting of E-cadherin. However, data available concerning the expression and the rol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cb636da45a4c026b1fad5ce58af79eb
https://doi.org/10.1158/0008-5472.sabcs13-p4-07-18
https://doi.org/10.1158/0008-5472.sabcs13-p4-07-18
Autor:
Marco A. Pierotti, Roberto Agresti, Sylvie Ménard, Giulia Bianchi, Gabriella Mariani, Giovanna Trecate, Cristina Ferraris, Mario Rampa, Marco Greco, Maria Luisa Carcangiu, Angela Moliterni, Gabriele Martelli, Giuseppe Capri, Elda Tagliabue, Marco Sandri, Massimiliano Gennaro, Martin Langer, Laura Lozza, Ilaria Maugeri, Cristina Pellitteri
Publikováno v:
Cancer. 120:885-893
BACKGROUND Although axillary surgery is still considered to be a fundamental part of the management of early breast cancer, it may no longer be necessary either as treatment or as a guide to adjuvant treatment. The authors conducted a single-center r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::231990d73f3c4fb14587e4f642e488bd
https://doi.org/10.1002/cncr.28499
https://doi.org/10.1002/cncr.28499
Autor:
Viola Regondi, Piera Aiello, Patrizia Casalini, Manuela Ratti, C. Ghirelli, Denis Cominetti, Tiziana Triulzi, Monica Tortoreto, Angela Moliterni, Martina Di Modica, Maria Luisa Carcangiu, Elda Tagliabue, Andrea Balsari
Publikováno v:
International Journal of Cancer. 134:2789-2797
Altered degradation and deposition of extracellular matrix are hallmarks of tumor progression and response to therapy. From a microarray supervised analysis on a dataset of chemotherapy-treated breast carcinoma patients, maspin, a member of the serpi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c120caa9a9a7ce0937c432c5b2097240
https://doi.org/10.1002/ijc.28608
https://doi.org/10.1002/ijc.28608
Autor:
Xavier Pivot, Louise Provencher, Vladimir Semiglazov, Mauro Mansutti, I Smirnova, Nicola Moore, Angela Moliterni, Steve Chan, Arlene Chan, Mikhail Lichinitser, Andrew M Wardley, Sergio Vicente Serrano, L. Gianni, Gilles Romieu, Oleg Lipatov, Richard Greil, S. Prot, Fabrice Andre
Publikováno v:
Cancer Research. 71:S4-8
Background: H + taxane is an established and effective first-line treatment for HER2−positive LR/mBC. Preclinical data provide the rationale for combining BEV and H in HER2−positive LR/mBC but clinical data in this setting are limited to single-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29e750274428d14eacca65f8de0e6af6
https://doi.org/10.1158/0008-5472.sabcs11-s4-8
https://doi.org/10.1158/0008-5472.sabcs11-s4-8
Autor:
Angelica Fasolo, Alfonso Marchianó, Gabriella Mariani, Luca Gianni, Angela Moliterni, Milvia Zambetti, Fausto Petrelli, Pinuccia Valagussa
Publikováno v:
Clinical Breast Cancer. 7:321-325
Background Capecitabine is a fluoropyrimidine carbamate that acts as a prodrug, mimics continuous infusion of 5-fluorouracil (5-FU), and has encouraging antitumor activity in women with metastatic breast cancer. We performed a feasibility study in wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d68a3a61031ed4d5af90d0ae6173c1c
https://doi.org/10.3816/cbc.2006.n.044
https://doi.org/10.3816/cbc.2006.n.044
Autor:
Romano Demicheli, Milvia Zambetti, Gianni Bonadonna, Angela Moliterni, Michael W. Retsky, William J. M. Hrushesky, P. Valagussa, Rosalba Miceli
Publikováno v:
Annals of Oncology. 16:1449-1457
Purpose: The aim of this study was to better understand human breast cancer biology by studying how the timing of metastasis following primary resection is affected by adjuvant CMF (cyclophoshamide, methotrexate, 5-fluorouracil) chemotherapy. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2bac2a0b97bcf004ef78ece8ccb65d
https://doi.org/10.1093/annonc/mdi280
https://doi.org/10.1093/annonc/mdi280
Autor:
Angela Moliterni, Gabriella Mariani, P. Valagussa, Matteo Duca, Giulia Galli, F. de Braud, Leonardo Ferrari, Silvia Damian, G. Capri, Giancarlo Bianchi, Salvatore Cavalieri, Stefania Cresta
Publikováno v:
Annals of Oncology. 28:vi34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4963ccb060d06467697c2ce122aed7dd
https://doi.org/10.1093/annonc/mdx424.033
https://doi.org/10.1093/annonc/mdx424.033
Autor:
Domenico Magazzu, José Baselga, Mikhail Byakhov, Federico Vazquez, Vladimir Semiglazov, Bozhok Aa, Milvia Zambetti, Ana Lluch, Sergei Tjulandin, Jutta Steinseifer, Mauro Mansutti, Luca Gianni, Dominik Heinzmann, Pinuccia Valagussa, Belén Ojeda, Wolfgang Eiermann, Angela Moliterni, Mikhail Lichinitser, Miguel Angel Climent, Eva Ciruelos
Publikováno v:
The Lancet. Oncology. 15(6)
Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b370c2781f70ba83c11a57f59d51bb
https://pubmed.ncbi.nlm.nih.gov/30507430
https://pubmed.ncbi.nlm.nih.gov/30507430